You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back

Amoxil - European Harmonisation process

On 25 June 2015, the European Medicines Agency completed a review of Amoxil. The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that there was a need to harmonise the prescribing information for Amoxil in the European Union (EU).
Please note that the Amoxil SPCs and PILs were updated on 21st April 2016 in line with this European Harmonisation process. Please follow the links below for further information.

Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971 Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Amoxil is a registered trademark of the GlaxoSmithKline group of companies